Search Result

Results for "

FGFR inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	FGFR (236) Akt (2) AMPK (3) Anaplastic lymphoma kinase (ALK) (2) Apoptosis (33) ATP Synthase (1) Aurora Kinase (4) Autophagy (20) Bcl-2 Family (1) Bcr-Abl (7) c-Fms (11) c-Kit (29) c-Met/HGFR (3) Caspase (1) CDK (3) Checkpoint Kinase (Chk) (1) Collagen (1) Cytochrome P450 (3) Discoidin Domain Receptor (1) Drug Metabolite (3) Drug-Linker Conjugates for ADC (1) EGFR (5) Endogenous Metabolite (5) ERK (3) FAK (3) FLT3 (15) GSK-3 (1) HDAC (1) Insulin Receptor (1) Isotope-Labeled Compounds (9) JAK (1) LIM Kinase (LIMK) (1) MAP3K (1) Mitosis (1) Necroptosis (1) NOD-like Receptor (NLR) (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (1) PDGFR (61) Peptide-Drug Conjugates (PDCs) (1) PROTACs (4) Pyroptosis (1) Raf (3) Reactive Oxygen Species (ROS) (1) Reference Standards (21) RET (10) Ribosomal S6 Kinase (RSK) (1) SHP2 (1) Src (22) Syk (1) TNF Receptor (1) Trk Receptor (1) VEGFR (79)
By Research Areas:	Cancer (248) Cardiovascular Disease (7) Endocrinology (1) Infection (2) Inflammation/Immunology (10) Metabolic Disease (3) Neurological Disease (3)
Oligonucleotides:	Antisense Oligonucleotides (2)

262

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: FGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156019

FGFR1 inhibitor-10	FGFR	Cancer
FGFR1 inhibitor-10 (Compound 4i) is an *FGFR1* inhibitor (IC₅₀: 28 nM). FGFR1 inhibitor-10 inhibits the phosphorylation of FGFR1. FGFR1 inhibitor-10 has anti-angiogenic, anti-invasion activity, and anti-tumor effect .

HY-149488

FGFR1 inhibitor-9	FGFR	Cancer
FGFR1 inhibitor-9 (Compound 7) is an *FGFR1* inhibitor (IC₅₀s: 0.85 nM). FGFR1 inhibitor-9 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-9 has anticancer activity .

HY-149487

FGFR1 inhibitor-8	FGFR	Cancer
FGFR1 inhibitor-8 (Compound 9) is a *FGFR1* inhibitor (IC₅₀s: 0.5 nM). FGFR1 inhibitor-8 binds to the ATP-binding pocket of FGFR1. FGFR1 inhibitor-8 has anticancer activity .

HY-169710

FGFR1 inhibitor-16	FGFR	Cancer
FGFR1 inhibitor-16 (Compound 89) is an *FGFR1* inhibitor. FGFR1 inhibitor-16 exhibits an inhibitory rate of 53.00% against *FGFR1* at a concentration of 50 μM and 24.95% at 10 μM. FGFR1 inhibitor-16 can be used in the study of cancer .

HY-169669

FGFR1 inhibitor-17	FGFR	Cancer
FGFR1 inhibitor-17 (Compound 92) is a potent *FGFR1* inhibitor. FGFR1 inhibitor-17 is promising for research of cancers .

HY-172618

FGFR1 inhibitor-18	FGFR	Cancer
FGFR1 inhibitor-18 (compound 16) is a potent *FGFR1* inhibitor with an IC₅₀ value of 1.31 nM. FGFR1 inhibitor-18 can occupy within the ATP-binding pocket of the target FGFR1 .

HY-W261325

FGFR1 inhibitor-15	FGFR	Cancer
FGFR1 inhibitor-15 (Compound 23) is an *FGFR1* inhibitor with an IC₅₀ of 27 μM. FGFR1 inhibitor-15 can be used in the study of cancer .

HY-156790

FGFR3-IN-6	FGFR	Cancer
FGFR3-IN-6 is a potent and selective FGFR3 inhibitor with IC₅₀ value less than 350 nM. FGFR3-IN-6 can be used in research of cancer .

HY-156791

FGFR3-IN-7	FGFR	Cancer
FGFR3-IN-7 is a potent and selective FGFR3 inhibitor with IC₅₀ value less than 350 nM. FGFR3-IN-7 can be used in research of cancer .

HY-143272

FGFR1 inhibitor-6	FGFR	Cancer
FGFR1 inhibitor-6 is a potent *FGFR1* inhibitor with an IC₅₀ value of 16.31 nM. FGFR1 inhibitor-6 shows cytotoxic activities. FGFR1 inhibitor-6 induces apoptosis and cell cycle arrest at pre-G1 and G2/M phase .

HY-W801893

FGFR1 inhibitor-13	FGFR	Cancer
FGFR1 inhibitor-13 (compound 1) is an FGFR1 inhibitor with an IC₅₀ of 4.2 μM .

HY-139376

FGFR1 inhibitor-2	FGFR	Cancer
FGFR1 inhibitor-2 is a *FGFR1* inhibitor (IC₅₀ is 4.55 μM in MDA-MB-231 cells). FGFR1 inhibitor-2 can be used for the research of metastatic triple-negative breast cancer .

HY-169623

FGFR1 inhibitor-14	FGFR	Cancer
FGFR1 inhibitor-14 (compound 28) is a *FGFR1* inhibitor, which can be used in anti-cancer research .

HY-149486

FGFR1 inhibitor 7	FGFR	Cancer
FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC₅₀ value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC₅₀ of 2.1 μM .

HY-163273

FGFR4-IN-17	FGFR	Cancer
FGFR4-IN-17 (Compound (S)-23) is a piperazinyl diflurindan derivative containing pyridinyl. FGFR4-IN-17 is a *FGFR* inhibitor with IC₅₀ values of 24.2, 16.1, 78.0, and 68.0 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FGFR4-IN-17 has antitumor activity .

HY-158098

FGFR1 inhibitor-11	FGFR	Metabolic Disease
FGFR1 inhibitor-11 (compound 5g) binds to *FGFR1, inactivation of its downstream ERK1/2 and IκBα/NF-κB signaling inhibited RANKL-induced osteoclastogenesis. FGFR1 inhibitor*-11 has oral bioactivity .

HY-114311

FGFR1/DDR2 inhibitor 1 1 Publications Verification	FGFR Discoidin Domain Receptor	Cancer
FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC₅₀ values of 31.1 nM and 3.2 nM, respectively. Antitumor activity .

HY-15813

FIIN-1 FGFR irreversible inhibitor-1	FGFR	Cancer
FIIN-1 is a potent, irreversible, selective *FGFR* inhibitor. FIIN-1 binds to *FGFR1/2/3/4* and Flt1/4 with K_ds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC₅₀s of FIIN-1 are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively .

HY-159503A

Segigratinib hydrochloride 3D185; HH185	FGFR c-Fms	Cancer
Segigratinib hydrochloride (3D185) is a potent inhibitor of *FGFR1/2/3* and CSF-1R; The IC₅₀ values for FGFR1, FGFR2, FGFR3 and CSF-1R are 0.5, 1.3, 3.6 and 3.8 nM, respectively. Segigratinib hydrochloride has antitumor activity .

HY-123134

FIIN-4	FGFR	Cancer
FIIN-4 is a first-in-class, orally active and covalent *FGFR* inhibitor with IC₅₀s of 2.6 nM, 2.6 nM, 5.6 nM, 9.2 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. FIIN-4 can inhibit metastatic tumor growth.

HY-163527

FGFR-IN-13	FGFR	Cancer
FGFR-IN-13 (compound III-30) is an irreversible covalent fibroblast growth factor receptor (FGFR) inhibitor. FGFR-IN-13 regulates endogenous *FGFR1(IC₅₀*=0.20±0.02 nM) and *FGFR4(IC₅₀*=0.40±0.03 nM) mediated signaling pathways by inhibiting the expression of key proteins. FGFR-IN-13 inhibits total-PARP and Bcl-2 protein expressions, and promote Cleaved-PARP and Bax protein expressions in a dose-dependent manner. FGFR-IN-13 has significant antitumor activity and oral activity .

HY-177276

FGFR-IN-22	FGFR	Cancer
FGFR-IN-22 (Compound 23) is a *FGFR* inhibitor with IC₅₀s of 0.631, 1.26, 0.851 and 1 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-22 effectively inhibits cell proliferation that depends on the FGFR1 and FGFR3 signaling pathway. FGFR-IN-22 can be used for cancers such as chronic lymphocytic leukemia (CLL) research .

HY-161326

CXF-007	FGFR	Cancer
CXF-007 is a potent and specific *FGFR4* inhibitor with a IC₅₀ value of 7 nM. CXF-007 has antitumor activity .

HY-112412

PDGFR Tyrosine Kinase Inhibitor III PDGF Receptor Tyrosine Kinase inhibitor III	PDGFR	Neurological Disease
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .

HY-150026

Multi-kinase-IN-2	VEGFR PDGFR FGFR c-Kit Akt Src Apoptosis	Cancer
Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and *FGFR-1, as well as LYN* and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity .

HY-172787

FGFR4-IN-23	FGFR Akt AMPK	Cancer
FGFR4-IN-23 (compound 48c) is a *FGFR4* inhibitor with an IC₅₀ value of 2.9 nM against *FGFR4* ^WT kinase. FGFR4-IN-23 inhibits the phosphorylation of *FGFR4, AKT* and MAPK .

HY-151903S

FGFR2/3-IN-1	FGFR	Cancer
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC₅₀s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC₅₀s of 2.7 nM and 6.1 nM, respectively .

HY-147515

FGFR4-IN-11	FGFR	Cancer
FGFR4-IN-11 (Compound 30) is a potent, selective, covalent *FGFR4* inhibitor with an IC₅₀ of 2.1 nM. FGFR4-IN-11 significantly inhibits the FGF19/FGFR4 signaling pathway and shows antitumor activity .

HY-101466

E7090	FGFR	Cancer
E7090 is an orally available, potent, and selective *FGFR* inhibitor with IC₅₀s of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for *FGFR1/FGFR2/FGFR3/FGFR4*, respectively .

HY-148779

FGFR3-IN-5	FGFR	Cancer
FGFR3-IN-5 is a potent and selective *FGFR3* inhibitor with IC₅₀ values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1, respectively. FGFR3-IN-5 can be used in research of cancer .

HY-155028

FGFR-IN-11	FGFR	Cancer
FGFR-IN-11 (compound I-5) is an orally active and covalent *FGFR* inhibitor with IC₅₀ values of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3), and 1.8 nM (FGFR4), respectively. FGFR-IN-11 inhibits multiple cancer cell proliferation with nanomolar activity. FGFR-IN-11 inhibits tumor growth significantly in xenograft mice models .

HY-144759

FGFR4-IN-9	FGFR	Cancer
FGFR4-IN-9 (Compound 6O) is a selective *FGFR4* inhibitor with an IC₅₀ of 75.3 nM. FGFR4-IN-9 effectively inhibits both the growth and angiogenesis of HCC .

HY-146541

FGFR4-IN-10	FGFR	Cancer
FGFR4-IN-10 (compound 5a) is a potent and selective *FGFR4* inhibitor with an IC₅₀ value of 70.7 nM. FGFR4-IN-10 shows no inhibition against other FGFR family members, i.e. FGFR1, FGFR2 and FGFR3 .

HY-170919

FGFR2/3-IN-2	FGFR	Cancer
FGFR2/3-IN-2 (compound 10) is an orally active *FGFR2* and *FGFR3* inhibitor. FGFR2/3-IN-2 inhibits *FGFR2* and *FGFR3* with IC₅₀s of 3.7 nM and 31.2 nM (preincubation time 1 h), respectively. FGFR2/3-IN-2 spares *FGFR1/4* and other kinases without causing diarrhea and serum phosphate elevation in vivo. FGFR2/3-IN-2 induces tumor stasis or regression in the SNU-16 gastric cancer model .

HY-145231

FGFR2-IN-2	FGFR	Cancer
FGFR2-IN-2 (Compound 38) is a selective *FGFR2* inhibitor with IC₅₀s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively .

HY-148778

FGFR3-IN-4	FGFR	Cancer
FGFR3-IN-4 is a selective *FGFR3* inhibitor, with an IC₅₀ value of less than 50 nM. FGFR3-IN-4 is at least 10 fold more selective for FGFR3 than for FGFR1 .

HY-163620

LHQ490	FGFR Apoptosis	Cancer
LHQ490 is a selective *FGFR2* inhibitor, with an IC₅₀ of 5.2 nM. LHQ490 efficiently inhibits the proliferation of BaF3-FGFR2 cells with an IC₅₀ value of 1.4 nM. LHQ490 inhibits FGFR2-driven cancer cell proliferation and induces apoptosis of FGFR2-driven cancer cells .

HY-18602

FIIN-2	FGFR	Cancer
FIIN-2 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 3.1, 4.3, 27, and 45 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-145043

FGFR-IN-1	FGFR	Cancer
FGFR-IN-1 is a potent *FGFR* inhibitor with an IC₅₀ of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219) .

HY-145230

FGFR2-IN-1	FGFR	Others
FGFR2-IN-1 is a selective *FGFR2* inhibitor with an IC₅₀ of 140 nM.

HY-156704

FGFR4-IN-16	FGFR	Cancer
FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of *FGFR-4* for cancer research .

HY-18603

FIIN-3	EGFR FGFR	Cancer
FIIN-3 is an irreversible inhibitor of *FGFR* with an IC₅₀ of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively.

HY-168653

FGFR-IN-15	FGFR	Cancer
FGFR-IN-15 (compound 18i) is a pan-FGFR inhibitor with potently inhibitory activity against *FGFR1-4*. .

HY-158010

FGFR3-IN-8	FGFR	Cancer
FGFR3-IN-8 (example91) is a selective *FGFR3* inhibitor .

HY-158011

FGFR3-IN-9	FGFR	Cancer
FGFR3-IN-9 (example27) is a selective *FGFR3* inhibitor .

HY-161610

FGFR4-IN-21	FGFR	Cancer
FGFR4-IN-21 (Compd 4c) is a *FGFR4* inhibitor with an IC₅₀ of 33 nM. FGFR4-IN-21 can be used for hepatocellular carcinoma research .

HY-13304

LY2874455 3 Publications Verification	FGFR	Cancer
LY2874455 is a *pan-FGFR* inhibitor with IC₅₀s of 2.8, 2.6, 6.4, 6 nM for *FGFR1, FGFR2, FGFR3, FGFR4*, respectively.

HY-142921

FGFR-IN-2	FGFR	Cancer
FGFR-IN-2 (compound 1) is a potent *FGFR* inhibitor with IC₅₀s of 7.3 nM, 4.3 nM, 7.6 nM, 11 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FGFR-IN-2 has the potential for cancer research .

HY-162865

FGFR2-IN-3	FGFR	Cancer
FGFR2-IN-3 is an inhibitor of fibroblast growth factor receptor 2 (FGFR2). FGFR2-IN-3 has good binding properties, forming key interactions and inducing conformational changes in FGFR2. FGFR2-IN-3 can be used for research on tumors .

HY-19957

Zoligratinib 3 Publications Verification Debio 1347; CH5183284	FGFR	Cancer
Zoligratinib (Debio 1347) is an orally available and selective *FGFR* inhibitor with IC₅₀s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively.

Cat. No.	Product Name

HY-L016

Protein Tyrosine Kinase Compound Library

1,402 compounds

Protein tyrosine kinases (PTKs) are key signaling molecules and important drug targets. Two classes of PTKs are present in cells: the transmembrane receptor PTKs (RTKs) and the nonreceptor PTKs. The RTK family includes the receptors for insulin and for many growth factors, such as EGFR, FGFR, PDGFR, VEGFR, and NGFR. RTKs are transmembrane glycoproteins that are activated by the binding of their ligands, and they transduce the extracellular signal to the cytoplasm by phosphorylating tyrosine residues on the receptors themselves (autophosphorylation) and on downstream signaling proteins. Their principal functions of PTKs involve the regulation of multicellular aspects of the organism. Cell to cell signals concerning growth, differentiation, adhesion, motility, and death are frequently transmitted through tyrosine kinases. In humans, tyrosine kinases have been demonstrated to play significant roles in the development of many disease states, including diabetes and cancers.

MCE designs a unique collection of 1,402 compounds that act as a useful tool for PTKs-related drug screening and disease research.

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Fluorescent Dye
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively .

HY-159642G

TYRA-300 (GMP)	Fluorescent Dye
TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TYRA-300 GMP is an orally active, selective inhibitor for *FGFR3* with an IC₅₀ of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors .

Cat. No.	Product Name	Type

HY-10407G

SU 5402 (GMP)	Biochemical Assay Reagents
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, *FGFR1, and PDGFRβ*, respectively .

HY-159642G

TYRA-300 (GMP)	Biochemical Assay Reagents
TYRA-300 GMP is TYRA-300 (HY-159642) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TYRA-300 GMP is an orally active, selective inhibitor for *FGFR3* with an IC₅₀ of 11 nM. TYRA-300 GMP exhibits antitumor efficacy against urothelial cancers and solid tumors .

Cat. No.	Product Name	Target	Research Area

HY-P3695

VSPPLTLGQLLS	FGFR	Cancer
VSPPLTLGQLLS is a small peptide *FGFR3* inhibitor, peptide P3, inhibits *FGFR3* phosphorylation. VSPPLTLGQLLS inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .

HY-P3695A

VSPPLTLGQLLS TFA	FGFR	Cancer
VSPPLTLGQLLS TFA is a small peptide *FGFR3* inhibitor, peptide P3, inhibits *FGFR3* phosphorylation. VSPPLTLGQLLS TFA inhibits 9-cisRA-induced tracheal lymphangiogenesis and blocks lymphatic endothelial cell (LEC) proliferation, migration, and tubule formation .

HY-P10870

Pep1-DNP conjugate 9	Peptide-Drug Conjugates (PDCs) FGFR Apoptosis	Cancer
Pep1-DNP conjugate 9 is a functionalized peptide which is composed of the DNP-Hapten and the FGFR1 binding peptide. Pep1-DNP conjugate 9 exhibits good affinity to *FGFR1* with K_D of 5.01 μM. Pep1-DNP conjugate 9 recruits anti-DNP antibodies to the surface of FGFR1-positive cells, inhibits the FGF2-induced proliferation in rat skeletal myoblast cells, and induces apoptosis. Pep1-DNP conjugate 9 exhibits antitumor efficacy in mouse models .

Cat. No.	Product Name	Target	Research Area

HY-P991583

GP369	FGFR ERK	Cancer
GP369 is a humanized *FGFR2-IIIb*-specific antibody. GP369 significantly inhibits the proliferation of tumor cells. GP369 can significantly inhibit phosphorylation of FGFR2 and downstream signaling pathways. GP369 can be used for research on cancer such as gastric cancer and breast cancer .

HY-P991584

HuGAL-FR21	FGFR	Cancer
HuGAL-FR21 is a humanized antiFGFR2IIIb IgG1 monoclonal antibody. HuGAL-FR21 can block the binding of FGF2, FGF7, and FGF10 to FGFR2IIIb and inhibit FGF-induced phosphorylation of FGFR2IIIb. HuGAL-FR21 can downregulate the expression of *FGFR2* in SNU-16 cells. HuGAL-FR21 shows the significant anti-tumor activity in athymic nude mice bearing gastric cancer xenograft models. HuGAL-FR21 can be used for research on cancer such as gastric cancer .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0060

Ferulic acid 10+ Cited Publications Coniferic acid	Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Monophenols other families Simple Phenylpropanols Sunscreen Phenols Phenylpropanoids Cosmetic Research Disease Research Fields Cancer	FGFR Endogenous Metabolite
Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N0060A

Ferulic acid sodium 10+ Cited Publications Coniferic acid sodium	Structural Classification Monophenols other families Classification of Application Fields Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Endogenous metabolite Disease Research Fields Cancer	FGFR Endogenous Metabolite Reactive Oxygen Species (ROS)
Ferulic acid sodium is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively.

HY-N0060R

Ferulic acid (Standard) Coniferic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Monophenols other families Simple Phenylpropanols Source classification Phenols Phenylpropanoids Plants Endogenous metabolite	Reference Standards FGFR Endogenous Metabolite
Ferulic acid (Standard) is the analytical standard of Ferulic acid. This product is intended for research and analytical applications. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-N7715

Ferulic acid acyl-β-D-glucoside Ferulic acid glucoside	Structural Classification Monophenols Classification of Application Fields Simple Phenylpropanols Source classification Rosaceae Other Diseases Phenols Phenylpropanoids Plants Aruncus sylvester Kostel. Disease Research Fields	Drug Metabolite
Ferulic acid acyl-β-D-glucoside (Ferulic acid glucoside) is a metabolite of Ferulic Acid (HY-N0060). Ferulic acid acyl-β-D-glucoside can be isolated from flaxseed extract. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀ values of 3.78 and 12.5 μM for *FGFR1* and *FGFR2*, respectively .

HY-N0183

Formononetin Maximum Cited Publications 18 Publications Verification Biochanin B; Flavosil; Formononetol	Cardiovascular Disease Structural Classification Classification of Application Fields Source classification Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Flavonoids other families Leguminosae Sunscreen Cosmetic Research Glycyrrhiza uralensis Fisch. Disease Research Fields Isoflavones	FGFR Apoptosis
Formononetin is a potent *FGFR2* inhibitor with an IC₅₀ of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .

HY-N0183R

Formononetin (Standard) Biochanin B (Standard); Flavosil (Standard); Formononetol (Standard)	Structural Classification Flavonoids other families Leguminosae Source classification Astragalus membranaceus var. mongholicus (Bunge)P.K.Hsiao Plants Glycyrrhiza uralensis Fisch. Isoflavones	Reference Standards FGFR Apoptosis
Formononetin (Standard) is the analytical standard of Formononetin. This product is intended for research and analytical applications. Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth .

HY-N9507

Picrasidine Q	Alkaloids Structural Classification other families Classification of Application Fields Source classification Quinoline Alkaloids Plants Disease Research Fields Indole Alkaloids Cancer	Apoptosis FGFR
Picrasidine Q, an alkaloid component extracted from Angelica keiskei species, has the capacity of anti-cell transformation and anti-cancer. Picrasidine Q induces cell apoptosis and G1 phase arrest in human esophageal cancer cell lines, and directly inhibits *FGFR2* kinase activity .

HY-W011873R

Palmitoleic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Reference Standards Endogenous Metabolite
Pazopanib (Hydrochloride) (Standard) is the analytical standard of Pazopanib (Hydrochloride). This product is intended for research and analytical applications. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Cat. No.	Product Name	Chemical Structure

HY-13311S

Infigratinib-d3
Infigratinib-d3 is a deuterated analog of infigratinib. Infigratinib is an effective inhibitor of the *FGFR* family, with IC₅₀ values of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for *FGFR1, FGFR2, FGFR3, and FGFR4*, respectively .

HY-N0060S1

Ferulic acid-13C3
Ferulic acid- ¹³C₃ is the ¹³C-labeled Ferulic acid. Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC50s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-10981S2

Lenvatinib-15N,d4
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, *FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities .

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-151903S

FGFR2/3-IN-1
FGFR2/3-IN-1 is a potent and selective FGFR2 and FGFR3 (FGFR) inhibitor with IC₅₀s of 1 nM and 0.5 nM, respectively. FGFR2/3-IN-1 displays >40-fold selectivity over FGFR1/FGFR4 and other kinome. FGFR2/3-IN-1 also inhibits FGFR3 V555L and V555M mutants with IC₅₀s of 2.7 nM and 6.1 nM, respectively .

HY-W754878

Pemigatinib-d6
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective *FGFR* inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively .

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against VEGFR2 with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ .

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-12047S

Ponatinib-d8
Ponatinib-d₈ is a deuterium labeled Ponatinib. Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride . Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-W705479

Pazopanib-d3 hydrochloride
Pazopanib-d₃ (hydrochloride) (GW786034-d₃ (hydrochloride)) is deuterium labeled Pazopanib (Hydrochloride). Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, *FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib . Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

HY-10208S2

Pazopanib-d3
Pazopanib-d₃ (GW786034-d₃) is deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, *FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively .

Cat. No.	Product Name		Classification

HY-159691

IONIS-FGFR4Rx ISIS 463588		Antisense Oligonucleotides
IONIS-FGFR4Rx (ISIS 463588) is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases .

HY-159691A

IONIS-FGFR4Rx sodium ISIS 463588 sodium		Antisense Oligonucleotides
IONIS-FGFR4Rx (ISIS 463588) sodium is an antisense inhibitor of fibroblast growth factor receptor 4 (FGFR4), which is promising for research of renal diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks